AI Article Synopsis
Article Abstract
The antiretroviral nanoparticle formulation laboratory at Creighton University School of Pharmacy & Health Professions is lead by Chris Destache. Over the past 4 years, this laboratory has been investigating the use of antiretroviral nanoparticles as a sustained drug delivery method for HIV-1-infected patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4155/tde.10.42 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
CCR5-ligand decorated rilpivirine lipid-based nanoparticles for sustained antiretroviral responses.
Nat Commun
January 2025
Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
Antiretroviral therapy (ART) improves the quality of life for those living with the human immunodeficiency virus type one (HIV-1). However, poor compliance reduces ART effectiveness and leads to immune compromise, viral mutations, and disease co-morbidities. Here we develop a drug formulation in which a lipid-based nanoparticle (LBNP) carrying rilpivirine (RPV) is decorated with the C-C chemokine receptor type 5 (CCR5) targeting peptide.
View Article and Find Full Text PDFPEGylated solid lipid nanoparticles for the intranasal delivery of combination antiretroviral therapy composed of Atazanavir and Elvitegravir to treat NeuroAIDS.
Int J Pharm
January 2025
College of Engineering, Virginia Commonwealth University, 601 West Main Street, Richmond, VA 23284, USA. Electronic address:
Intranasal drug administration offers a promising strategy for delivering combination antiretroviral therapy (cART) directly to the central nervous system to treat NeuroAIDS, leveraging the nose-to-brain route to bypass the blood-brain barrier. However, challenges such as enzymatic degradation in the nasal mucosa, low permeability, and mucociliary clearance within the nasal cavity must first be addressed to make this route feasible. To overcome these barriers, this study developed solid lipid nanoparticles (SLNs) with varying PEGylation levels (0 %, 5 %, 10 %, and 15 % w/w of PEGylated lipid), co-encapsulated with Elvitegravir (EVG) and Atazanavir (ATZ) as an integrase and protease inhibitor, respectively.
View Article and Find Full Text PDFTarget product profile for cell-based and gene-based therapies to achieve a cure for HIV.
Lancet HIV
January 2025
Africa Health Research Institute, Durban, South Africa; HIV Pathogenesis Programme, Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA; University College London, London, UK.
This target product profile (TPP) highlights the minimal and optimal characteristics for ex-vivo and in-vivo cell and gene therapy-based products aimed at achieving an HIV cure (ie, durable antiretroviral-free viral control). The need for an effective, safe, scalable, affordable, accessible, and acceptable cure for HIV infection remains a major global priority. The possibilities for cell and gene therapy-based products for an HIV cure are rapidly expanding.
View Article and Find Full Text PDFEfficacy and Possible Mechanism(s) of Action of Gallium Tetraphenylporphyrin Nanoparticles against HIV-TB Coinfection in an Granuloma Structure Model.
ACS Infect Dis
December 2024
Department of Pathology, Microbiology and Immunology, College of Medicine, University of Nebraska Medical Center, Omaha, Nebraska 68198, United States.
Coinfection of (Mtb) and human immunodeficiency virus-1 (HIV) is a significant public health concern. Treatment is challenging due to prolonged duration of therapy and drug interactions between antiretroviral therapy (ART) and anti-TB drugs. Noniron gallium -tetraphenyl porphyrin (GaTP), a heme mimetic, has shown broad antimicrobial activity.
View Article and Find Full Text PDFDevelopment of KSHV vaccine platforms and chimeric MHV68-K-K8.1 glycoprotein for evaluating the immunogenicity and efficacy of KSHV vaccine candidates.
mBio
December 2024
Department of Cancer Biology and Infection Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Article Synopsis
- Kaposi's sarcoma-associated herpesvirus (KSHV) is responsible for diseases like Kaposi's Sarcoma and has a high prevalence in sub-Saharan Africa, making vaccine development critical, but existing challenges include the absence of viable animal models for KSHV infection.
- The study created a chimeric mouse virus (MHV68-K-K8.1) to mimic KSHV infection and tested two K8.1 vaccines (mRNA-LNP and Ferritin nanoparticles) which successfully stimulated immune responses in mice.
- Results showed that mice vaccinated with K8.1 mRNA LNP vaccines had reduced viral levels and reactivation rates of the surrogate virus, indicating the potential effectiveness of these
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!